AUTHOR=Mukerjee Nobendu , Das Anubhab , Jawarkar Rahul D. , Maitra Swastika , Das Padmashree , Castrosanto Melvin A. , Paul Soumyadip , Samad Abdul , Zaki Magdi E. A. , Al-Hussain Sami A. , Masand Vijay H. , Hasan Mohammad Mehedi , Bukhari Syed Nasir Abbas , Perveen Asma , Alghamdi Badrah S. , Alexiou Athanasios , Kamal Mohammad Amjad , Dey Abhijit , Malik Sumira , Bakal Ravindra L. , Abuzenadah Adel Mohammad , Ghosh Arabinda , Md Ashraf Ghulam TITLE=Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer’s disease JOURNAL=Frontiers in Aging Neuroscience VOLUME=14 YEAR=2022 URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.878276 DOI=10.3389/fnagi.2022.878276 ISSN=1663-4365 ABSTRACT=
Alzheimer’s disease (AD) is a severe neurodegenerative disorder of the brain that manifests as dementia, disorientation, difficulty in speech, and progressive cognitive and behavioral impairment. The emerging therapeutic approach to AD management is the inhibition of β-site APP cleaving enzyme-1 (BACE1), known to be one of the two aspartyl proteases that cleave β-amyloid precursor protein (APP). Studies confirmed the association of high BACE1 activity with the proficiency in the formation of β-amyloid-containing neurotic plaques, the characteristics of AD. Only a few FDA-approved BACE1 inhibitors are available in the market, but their adverse off-target effects limit their usage. In this paper, we have used both ligand-based and target-based approaches for drug design. The QSAR study entails creating a multivariate GA-MLR (Genetic Algorithm-Multilinear Regression) model using 552 molecules with acceptable statistical performance (